Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2021

Feb 09, 2022

SELL
$2.39 - $4.0 $126,270 - $211,332
-52,833 Closed
0 $0
Q3 2021

Nov 15, 2021

SELL
$3.3 - $6.32 $12,771 - $24,458
-3,870 Reduced 6.83%
52,833 $213,000
Q2 2021

Aug 11, 2021

BUY
$6.32 - $14.02 $358,362 - $794,976
56,703 New
56,703 $367,000

Others Institutions Holding GMTX

About Gemini Therapeutics, Inc.


  • Ticker GMTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,244,500
  • Market Cap $1.05B
  • Description
  • Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 ...
More about GMTX
Track This Portfolio

Track Alps Advisors Inc Portfolio

Follow Alps Advisors Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Alps Advisors Inc, based on Form 13F filings with the SEC.

News

Stay updated on Alps Advisors Inc with notifications on news.